| Original language | English (US) |
|---|---|
| Pages (from-to) | 198-201 |
| Number of pages | 4 |
| Journal | Clinical Liver Disease |
| Volume | 20 |
| Issue number | 6 |
| DOIs | |
| State | Published - Dec 2022 |
All Science Journal Classification (ASJC) codes
- Hepatology
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Clinical Liver Disease, Vol. 20, No. 6, 12.2022, p. 198-201.
Research output: Contribution to journal › Review article › peer-review
TY - JOUR
T1 - Magnetic resonance imaging proton density fat fraction as an imaging-based biomarker of treatment response in patients with nonalcoholic steatohepatitis
AU - Stine, Jonathan G.
AU - Loomba, Rohit
N1 - Funding Information: This study was supported by National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health grant K23DK13190 (to J.G.S.). R.L. receives funding support from NCATS (grant 5UL1TR001442); National Institute of Diabetes and Digestive and Kidney Diseases (grants U01DK061734, U01DK130190, R01DK106419, R01DK121378, R01DK124318, and P30DK120515); National Heart, Lung, and Blood Institute (grant P01HL147835); and National Institute on Alcohol Abuse and Alcoholism (grant U01AA029019). Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease worldwide for which there remains no regulatory agency–approved drug therapy or cure. NAFLD encompasses a spectrum of histological features, including nonalcoholic fatty liver, nonalcoholic steatohepatitis (NASH), and cirrhosis. Invasive liver biopsy remains the gold standard for diagnosis and monitoring of treatment response in patients with NASH. Funding Information: This study was supported by National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health grant K23DK13190 (to J.G.S.). R.L. receives funding support from NCATS (grant 5UL1TR001442); National Institute of Diabetes and Digestive and Kidney Diseases (grants U01DK061734, U01DK130190, R01DK106419, R01DK121378, R01DK124318, and P30DK120515); National Heart, Lung, and Blood Institute (grant P01HL147835); and National Institute on Alcohol Abuse and Alcoholism (grant U01AA029019).
PY - 2022/12
Y1 - 2022/12
UR - http://www.scopus.com/inward/record.url?scp=85144317203&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85144317203&partnerID=8YFLogxK
U2 - 10.1002/cld.1249
DO - 10.1002/cld.1249
M3 - Review article
C2 - 36523866
AN - SCOPUS:85144317203
SN - 2046-2484
VL - 20
SP - 198
EP - 201
JO - Clinical Liver Disease
JF - Clinical Liver Disease
IS - 6
ER -